

Amendments to the Claims

Please amend Claims 1, 16, 17, and 18. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently Amended) A method of suppressing or eliminating tumor cells, comprising administering to a subject in need of suppressing or eliminating tumor cells a yeast neutral soluble glucan and at least one complement activating anti-tumor antibody directed to ~~the tumor cells or~~ stably expressed antigens of said tumor cells, the antibody being introduced via direct administration of antibody, wherein the glucan does not induce systemic release of inflammatory cytokines and the glucan and antibody together synergistically suppress or eliminate tumor cells.
2. (Cancelled)
3. (Previously Presented) The method of Claim 1, wherein the antibody is selected from trastuzumab, rituximab, cetuximab and combinations thereof.
4. (Original) The method of Claim 1, wherein the soluble beta glucan is administered parenterally.
- 5-13. (Cancelled)
14. (Previously Presented) The method of Claim 1, wherein the neutral soluble glucan is in a single helix conformation, a triple helix conformation, or a combination thereof.
15. (Cancelled)
16. (Currently Amended) A method of suppressing or eliminating tumor cells stably expressing trastuzumab-specific antigen, comprising administering a neutral soluble

glucan and trastuzumab to a subject in need of suppressing or eliminating tumor cells stably expressing trastuzumab-specific antigen, wherein the glucan does not induce systemic release of inflammatory cytokines and the glucan and trastuzumab together synergistically suppress or eliminate tumor cells stably expressing trastuzumab-specific antigen.

17. (Currently Amended) A method of suppressing or eliminating mammary carcinoma stably expressing trastuzumab-specific antigen, comprising administering a neutral soluble glucan and trastuzumab to a subject having mammary carcinoma stably expressing trastuzumab-specific antigen, wherein the glucan does not induce systemic release of inflammatory cytokines and the glucan and trastuzumab together synergistically suppress or eliminate mammary carcinoma stably expressing trastuzumab-specific antigen.
18. (Currently Amended) A method of regressing tumor growth stably expressing trastuzumab-specific antigen, comprising administering a neutral soluble glucan and trastuzumab to a subject having a tumor stably expressing trastuzumab-specific antigen to synergistically regress tumor growth stably expressing trastuzumab-specific antigen, wherein the glucan does not induce systemic release of inflammatory cytokines.